

## CURRICULUM VITAE

Dr Alasdair Stamps

+44 1865 784737    +44 7789 485541  
\* [alasdair.stamps@biotechnet.co.uk](mailto:alasdair.stamps@biotechnet.co.uk)

### SUMMARY

- Director and co-founder of BioPartner.co.uk Ltd., a company providing international business services to the UK lifescience sector
- Executive-level experience in biopharmaceutical fundraising, partnering, licensing and due diligence
- R&D experience in oncology, inflammatory disease research, discovery technologies and software interface development

### CAREER

**Current**    **Co-Founder and Company Director, BioPartner.co.uk Ltd - [www.biopartner.co.uk](http://www.biopartner.co.uk)**  
BioPartner is a UK government Accredited Trade Organisation providing international business partnering opportunities for UK lifescience companies and organisations.  
**Founder Member in Oxfordshire BiotechNet - [www.biotechnet.co.uk](http://www.biotechnet.co.uk)**

#### **2005- present Consultant to Oxford Biotherapeutics Ltd, Oxford**

A consortium of experts from the bioindustry, which provides business leads for its members upon whom it calls to provide input as required for project work  
Oxford BioTherapeutics is a biopharmaceutical SME that is exploiting proteomic discovery to generate antibody therapies combined with tailored diagnostics in oncology. I have been integrally involved the transformation of the company from a platform discovery business into a biopharmaceutical player with a near-to-clinic therapeutic pipeline. I have a broad set of responsibilities underpinning the development of the company through:

- supporting a major VC funding round
- business development (collaborative deals: Amgen 2007, GSK 2009)
- membership of the Joint Steering Committees of the various collaborations
- internal discovery activities from target identification to preclinical drug development
- building an intellectual property portfolio
- building a Biology team

#### **2003 -2006 Principal Scientist at UCB/Celltech, UK**

Reporting to the VP Oncology, I liaised with the Business Development, Strategic Alliances, Patents and Oncology Biology departments to evaluate licensing opportunities, collate and report competitor intelligence and manage an internal patent portfolio.

**1998 - 2003 Head of Target Informatics at Oxford GlycoSciences plc, Oxford**

Oxford GlycoSciences (OGS) was a biopharmaceutical company applying proteomics and genomics for the discovery, development and commercialisation of therapeutic products. OGS established the world's largest proteomic data repository.

I managed a small team to build the company's internal discovery platform. I was responsible for

- Developing an integrated bioinformatic platform for proteomic target discovery
- Discovery and evaluation of >300 oncology targets
- Patent applications for 25 oncology targets
- Publication of peer-reviewed scientific articles and reviews
- Presentations to international conferences and potential business partners

**1995 - 1998 Senior Scientist at Yamanouchi Research Institute, Oxford**

Yamanouchi, now Astellas, was the first Japanese company to establish a foothold in the Oxford Cluster.

**pre-1995 Academic fellowships in Oncology at Royal Free Hospital, and Institute of Cancer Research, London**

The Institute of Cancer Research, now CRUK, is the UK's foremost cancer research establishment. My postdoctoral training included viral oncology and cancer cell immortalisation. I developed a number of novel molecular methods for gene discovery.

**EDUCATION & QUALIFICATIONS**

BSc in Biochemistry (Aberdeen 1984)

PhD in Molecular Biology (Glasgow 1988)

**OTHER RELEVANT EXPERIENCE**

South East Healthcare Technologies Alliance Board Member (2007- 2009)

Thames Valley Life Sciences Network Steering Group (2006- present)

Oxfordshire Bioinformatics Forum Steering Group (2003-2005)

Oxfordshire Bioscience Network Advisor (2002-2005)

Designated Individual (Human Tissue Authority) 2007-present

Biological Safety Officer and Radiological Protection Officer (previous)

**REFERENCES**

On request

## PUBLICATIONS

1. Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, Lu LS, Leach BI, Mason S, Stamps AC, Boyd RS, Pezzella F, Gatter KC, Harris AL.  
CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. *Br J Cancer*. 2006 Aug 7;95(3):298-306
2. Oxfordshire Biotechnology Cluster Report 2005  
[http://www.oxfordshirebioscience.com/seeb/images/publications/oxford\\_biotech\\_cluster.pdf](http://www.oxfordshirebioscience.com/seeb/images/publications/oxford_biotech_cluster.pdf)
3. Stamps AC, Terrett JA.  
Pharmacoproteomics. In Hall, Pirmohamed & Tucker (eds.) Pharmacogenetics, Marcel Dekker 2004
4. Stamps AC, Adam P, Terrett JA.  
Proteomics and Cancer. *Applied Genomics and Proteomics* 2004
5. McGowan SJ, Terrett JA, Brown C, et al.  
Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins. *Current Proteomics* 2004 Jan;1:41-8 <http://www.bentham.org/1-1/cp1-1/Andrew%20Llyall.pdf>
6. Stamps AC, Adam PJ, Terrett JA.  
A practical route to target discovery via proteomics. *Biosystems Solutions* 2003
7. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeier KF, Stamps AC, Herath A, Sim E, O'Hare MJ, Harris AL, Terrett JA.  
Arylamine N-acetyltransferase-1 (NAT-1) Is Highly Expressed in Breast Cancers and Conveys Enhanced Growth and Resistance to Etoposide in Vitro. *Molecular Cancer Research* 2003 Sept 1;1(11).
8. Boyd RS, Adam PJ, Patel S, Loader JA, Berry J, Redpath NT, Poyser HR, Fletcher GC, Burgess NA, Stamps AC, Hudson L, Smith P, Griffiths M, Willis TG, Karran EL, Oscier DG, Catovsky D, Terrett JA, Dyer MJ.  
Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B. *Leukemia*. 2003 Aug;17(8):1605-12.
9. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R, Turner P, Stamps A, McMillan D, Saville G, Ng S, Mason S, Snell D, Schofield D, Gong H, Townsend R, Gallagher J, Page M, Parekh R, Stubberfield C.  
Biochemical characterisation of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. *Biochem J*. 2003 Jul 15;373(Pt 2):423-35.
10. Stamps AC, Terrett JA, Adam PJ.  
Application of in situ RT-PCR to tissue microarrays. *J Nanobiotechnology* 2003 1:3
11. Adam P, Boyd R, Tyson K, Fletcher G, Stamps A, Hudson L, Poyser H, Redpath N, Griffiths M, Steers G, Harris A, Patel S, Berry J, Loader J, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA.  
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. *J Biol Chem*. 2003 Feb 21;278(8):6482-9.
12. Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, Tyson K, Terrett J, Box G, Eccles S, Page MJ.  
Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. *Int J Cancer*. 2002 Feb 1;974:416-24.
13. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J, Page M.  
Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. *Biochem Biophys Res Commun*. 2000 Oct 5;2763:1170-7.

14. Stamps A, Elmore MA, Hill ME, Makda AA, Kelly K, Finnen MJ.  
Mammalian lyso phosphatidic acyltransferases. *Research Disclosures*. 1997 400; 551-553. GenBank Accession numbers AF011374 and AF015811
15. Stamps A, Elmore MA, Hill ME, Kelly K, Makda AA, Finnen MJ.  
A human cDNA sequence with homology to non-mammalian lyso phosphatidic acid acyltransferases. *Biochem J*. 1997 326; 455-461. GenBank Accession number U75971
- Makda AA, Elmore MA, Hill ME, Stamps A, Tejura S, Finnen MJ.  
Cell type distribution and subcellular location of enzymes involved in the metabolism of acyl ethanolamines. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 1997 57; 264.
16. Makda AA, Elmore MA, Hill ME, Stamps A, Tejura S, Finnen MJ.  
Differential effects of CB1 and CB2 agonists on cAMP levels and MAP kinase activation in human peripheral blood mononuclear cells. *Biochem Soc Trans*. 1997 25; 217S.
17. Makda AA, Elmore MA, Hill ME, Stamps A, Tejura S, Finnen MJ.  
Differential effects of CB1 and CB2 agonists on cAMP levels and MAP kinase activation in human peripheral blood mononuclear cells. *Immunology*. 1996 89; S1, N131.
18. Birdsall SH, Stamps AC, Gusterson BA, Shipley JM, Gill SE, Cooper CS.  
No rearrangement of the CHOP and TLS/FUS genes in two cases of phyllodes tumor of the breast. *Cancer Genet Cytogenet*. 1996 87; 90-91.
19. Stamps AC, Davies SC, Burman J, O'Hare MJ.  
Analysis of proviral integration in human mammary epithelial cell lines immortalised using retroviral infection with a ts SV40 T-antigen construct. *Int J Cancer*. 1994 57; 865-874.
20. Eeles RA, Warren W, Stamps A.  
The PCR revolution. In: Yarnold J., Stratton M., McMillan T. (eds): *Molecular Biology for Oncologists*. 1993 Elsevier Science Publishers B.V., The Netherlands.
21. Eeles RA, Stamps A.  
Polymerase Chain Reaction PCR: The technique and its applications. 1993 R. G. Landes Company, Austin, Texas.
22. Stamps AC, Davies S, O'Hare MJ.  
The tumour suppressor gene status of conditionally immortalised human mammary epithelial cell lines. *The Breast* 1992 1; 153.
23. Stamps AC, Gusterson BA, O'Hare MJ.  
Are tumours immortal? *Eur J Cancer* 1992 28A; 1495-1500.
24. Eeles RA, Warren W, Stamps A.  
The PCR revolution. *Eur J Cancer* 1992 28; 289-293.
25. Gusterson BA, Anbazhagan R, Warren W, Midgely C, Lane DP, O'Hare M, Stamps A, Carter R, Jayatilake H.  
Expression of p53 in premalignant and malignant squamous epithelium. *Oncogene* 1991 6; 1785-1789.
26. Harrison TJ, Lin Y, Stamps A, Dusheiko G, Zuckerman AJ.  
Hepatitis B virus-associated hepatocellular carcinoma in African patients. *Cancer Detection & Prevention* 1990 14; 457-460.
27. Stamps AC, Campo MS.  
Mapping of two novel transcripts of bovine papillomavirus type 4. *J gen Virol*. 1988 69; 3033-3045.